Stock listing
Frankfurt:CUP Chugai Pharmaceutical Co., Ltd. Aktie
German listing (Frankfurt) of Chugai Pharmaceutical Co., Ltd. · home listing Tokyo:4519
Follow Chugai Pharmaceutical Co., Ltd. into a list and get an email when it puts out news.
Share price · FWB:CUP
€40.51 EUR -0.67 (-1.6%)
Close on Nov 20, 2026
- Day range
- €40.51 – €40.65 EURNov 20, 2026
- Market cap
- €66.67B EURAt the close on Nov 20, 2026 · price × 1.65B shares outstanding
- 52-week range
- €33.31 – €56.57 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €3,825 EURMedian day 0 shares · 44 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| OTC:CHGCY | $22.26 USD | -0.20 (-0.9%) | 218,409 | $22.81 | $22.81 | $22.01 | $22.46 | Close on Nov 20, 2026 |
| OTC:CHGCF | $44.81 USD | +0.488 (+1.1%) | 561 | $44.81 | $44.81 | $44.81 | $44.32 | Close on Nov 20, 2026 |
| Frankfurt:CUP | €40.51 EUR | -0.67 (-1.6%) | — | €40.54 | €40.65 | €40.51 | €41.18 | Close on Nov 20, 2026 |
| Munich:CUP | €40.08 EUR | -1.67 (-4.0%) | — | €40.64 | €40.64 | €40.08 | €41.75 | Close on Nov 20, 2026 |
| Dusseldorf:CUP | €39.61 EUR | -1.17 (-2.9%) | — | €40.09 | €40.58 | €39.61 | €40.78 | Close on Nov 20, 2026 |
| Frankfurt:CUP0 | €19.50 EUR | -0.40 (-2.0%) | — | €19.50 | €19.50 | €19.50 | €19.90 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:CUP · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €38.15 | -2.033 | -5.1% | €38.26 | €38.39 | €38.15 | 0 | |
| €40.18 | +2.181 | +5.7% | €39.97 | €40.22 | €39.97 | 708 | |
| €38.00 | -0.743 | -1.9% | €38.37 | €38.85 | €37.98 | 708 | |
| €38.74 | +0.352 | +0.9% | €38.74 | €38.74 | €38.74 | 78 | |
| €38.39 | +0.066 | +0.2% | €38.54 | €38.63 | €37.98 | 0 | |
| €38.32 | +0.967 | +2.6% | €38.39 | €38.74 | €38.13 | 502 | |
| €37.36 | -0.312 | -0.8% | €37.54 | €37.64 | €37.14 | 764 | |
| €37.67 | +0.078 | +0.2% | €37.84 | €37.84 | €37.46 | 12 | |
| €37.59 | -0.878 | -2.3% | €37.69 | €37.69 | €37.59 | 0 | |
| €38.47 | +0.276 | +0.7% | €38.44 | €38.64 | €38.32 | 2,600 | |
| €38.19 | +0.931 | +2.5% | €38.37 | €38.54 | €38.10 | 0 | |
| €37.26 | +1.112 | +3.1% | €37.26 | €37.26 | €37.06 | 0 | |
| €36.15 | +0.052 | +0.1% | €36.32 | €36.41 | €36.07 | 0 | |
| €36.10 | +0.943 | +2.7% | €36.11 | €36.11 | €35.88 | 0 | |
| €35.15 | -0.082 | -0.2% | €35.16 | €35.17 | €35.14 | 0 | |
| €35.24 | +0.16 | +0.5% | €35.25 | €35.49 | €35.18 | 0 | |
| €35.08 | +1.189 | +3.5% | €35.11 | €35.12 | €35.04 | 0 | |
| €33.89 | -0.853 | -2.5% | €33.96 | €33.99 | €33.66 | 0 | |
| €34.74 | +1.30 | +3.9% | €34.35 | €34.99 | €34.19 | 0 | |
| €33.44 | -0.049 | -0.1% | €33.50 | €33.50 | €33.31 | 0 | |
| €33.49 | -0.748 | -2.2% | €33.52 | €33.52 | €33.47 | 0 | |
| €34.24 | +0.074 | +0.2% | €34.17 | €34.27 | €34.16 | 0 | |
| €34.16 | +0.122 | +0.4% | €34.16 | €34.33 | €34.07 | 0 | |
| €34.04 | -0.216 | -0.6% | €34.16 | €34.20 | €33.80 | 0 | |
| €34.26 | +0.032 | +0.1% | €34.38 | €34.54 | €34.20 | 0 | |
| €34.22 | -0.148 | -0.4% | €33.90 | €34.28 | €33.65 | 0 | |
| €34.37 | -0.134 | -0.4% | €34.27 | €34.47 | €33.97 | 0 | |
| €34.51 | +0.74 | +2.2% | €34.67 | €34.93 | €34.44 | 0 | |
| €33.77 | -1.266 | -3.6% | €33.93 | €34.12 | €33.74 | 0 | |
| €35.03 | -1.278 | -3.5% | €35.02 | €35.22 | €35.00 | 0 | |
| €36.31 | -0.01 | 0.0% | €36.31 | €36.36 | €36.16 | 0 | |
| €36.32 | -0.876 | -2.4% | €36.40 | €36.47 | €36.31 | 0 | |
| €37.20 | -0.041 | -0.1% | €37.33 | €37.58 | €37.20 | 0 | |
| €37.24 | +0.30 | +0.8% | €37.15 | €37.30 | €36.92 | 0 | |
| €36.94 | -0.303 | -0.8% | €36.98 | €36.99 | €36.94 | 0 | |
| €37.24 | +0.196 | +0.5% | €37.35 | €37.36 | €37.24 | 0 | |
| €37.04 | +1.295 | +3.6% | €37.06 | €37.48 | €36.83 | 0 | |
| €35.75 | -0.671 | -1.8% | €35.83 | €35.95 | €35.52 | 0 | |
| €36.42 | +1.004 | +2.8% | €36.39 | €36.56 | €36.30 | 30 | |
| €35.42 | -0.136 | -0.4% | €35.56 | €35.87 | €35.35 | 0 | |
| €35.55 | +0.335 | +1.0% | €35.56 | €35.61 | €35.42 | 0 | |
| €35.22 | -0.896 | -2.5% | €35.45 | €35.82 | €35.00 | 0 | |
| €36.11 | -0.255 | -0.7% | €36.11 | €36.19 | €35.93 | 0 | |
| €36.37 | -0.133 | -0.4% | €36.43 | €36.43 | €35.82 | 0 | |
| €36.50 | -0.371 | -1.0% | €36.25 | €36.62 | €36.21 | 0 | |
| €36.87 | -0.721 | -1.9% | €36.87 | €37.39 | €36.80 | 0 | |
| €37.59 | +0.26 | +0.7% | €37.42 | €37.87 | €37.34 | 70 | |
| €37.33 | -0.11 | -0.3% | €36.96 | €37.48 | €36.93 | 80 | |
| €37.44 | +0.197 | +0.5% | €37.80 | €38.31 | €37.44 | 52 | |
| €37.25 | -0.544 | -1.4% | €37.62 | €37.90 | €37.18 | 39 | |
| €37.79 | +0.608 | +1.6% | €37.81 | €38.10 | €37.49 | 0 | |
| €37.18 | -0.625 | -1.7% | €37.13 | €37.46 | €37.03 | 0 | |
| €37.81 | +0.614 | +1.7% | €37.84 | €37.84 | €37.57 | 0 | |
| €37.19 | +0.113 | +0.3% | €37.18 | €37.55 | €37.13 | 0 | |
| €37.08 | -0.884 | -2.3% | €37.27 | €37.43 | €37.03 | 0 | |
| €37.96 | +0.557 | +1.5% | €37.68 | €37.99 | €37.50 | 35 | |
| €37.41 | +0.034 | +0.1% | €37.89 | €38.19 | €37.37 | 0 |
Splits
1 split · FWB:CUP · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 3-for-1 | Split |
- Ticker
- Frankfurt:CUP
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Oct 27, 2026
Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS)
Latest earnings call · Jul 24, 2026
Chugai Pharmaceutical (Tokyo:4519) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Oct 27, 2026
Q3 2026 Earnings Presentation
Earnings · 32 slides
Latest news
Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS)
Oct 27, 2026
Closed €37.59 (-2.3%) on Oct 27, 2026
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the nine months ended September 30, 2026)
Oct 27, 2026
Closed €37.59 (-2.3%) on Oct 27, 2026
F. Hoffmann-La Roche Announces Third Quarter Sales 2026
Oct 22, 2026
Closed €37.26 (+3.1%) on Oct 22, 2026
Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA
Sep 28, 2026
Closed €35.03 (-3.5%) on Sep 28, 2026
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors
Sep 9, 2026
Closed €36.11 (-0.7%) on Sep 9, 2026
Chugai and GSK Sign Exclusive License Agreement for Anti-Dengue Virus Antibody AID351
Aug 18, 2026
Closed €36.58 (-1.0%) on Aug 18, 2026
Chugai Announces 2026 2nd Quarter Results
Jul 27, 2026
Closed €36.58 (-7.1%) on Jul 27, 2026
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026)
Jul 24, 2026
Closed €39.37 (+3.5%) on Jul 24, 2026
F. Hoffmann-La Roche Announces Half Year Results 2026
Jul 23, 2026
Closed €38.02 (-2.4%) on Jul 23, 2026
Chugai Files New Drug Application in Japan for Sparsentan for the Treatment of IgA Nephropathy
Jun 22, 2026
Closed €40.60 (-0.2%) on Jun 22, 2026
Chugai Pharmaceutical Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 25 in the last 12 months · 31 in all · newest Oct 27, 2026 · oldest 2025
- Calls
- 9 calls with a replay · 9 with a transcript · latest Jul 24, 2026
- Decks
- 107 decks · latest Oct 27, 2026
Where Chugai Pharmaceutical Co., Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Tokyo:4519 中外製薬 · Home listing | Tokyo | Japan | JPY |
| OTC:CHGCY | OTC | United States | USD |
| OTC:CHGCF | OTC | United States | USD |
| gettex:CUP | gettex | Germany | EUR |
| Frankfurt:CUP · This page | Frankfurt | Germany | EUR |
| Tradegate:CUP | Tradegate | Germany | EUR |
| LS Exchange:857216 | LS Exchange | Germany | EUR |
| Lang & Schwarz:857216 | Lang & Schwarz | Germany | EUR |
| BMV:4519N | BMV | Mexico | MXN |
| Munich:CUP | Munich | Germany | EUR |
| Stuttgart:CUP | Stuttgart | Germany | EUR |
| Hamburg:CUP | Hamburg | Germany | EUR |
| Dusseldorf:CUP | Dusseldorf | Germany | EUR |
| gettex:CUP0 | gettex | Germany | EUR |
| Hanover:CUP | Hanover | Germany | EUR |
| BIVA:4519N | BIVA | Mexico | MXN |
| Frankfurt:CUP0 | Frankfurt | Germany | EUR |
| Munich:CUP0 | Munich | Germany | EUR |
Team and board
Officers
| Officer | Role |
|---|---|
| Osamu Okuda | Representative Director, President & CEO |
| Iwaaki Taniguchi | Director, Executive Vice President & CFO |
| Hitoshi Iikura | Director, Executive Vice President |
| Boris L. Zaïtra | Head of Corporate Business Development of Roche |
Board
| Director | Role |
|---|---|
| Boris L. Zaïtra | Head of Corporate Business Development of Roche |
| Hitoshi Iikura | Director, Executive Vice President |
| Iwaaki Taniguchi | Director, Executive Vice President & CFO |
| Masayoshi Higuchi | Audit & Supervisory Board Member (full-time) |
| Osamu Okuda | Representative Director, President & CEO |
| Shigehiro Yamada | Audit & Supervisory Board Member (full-time) |
| Teresa A. Graham | Director |
| Thomas Schinecker | Director |
Events
| Call | When | Status |
|---|---|---|
| Chugai Pharmaceutical (Tokyo:4519) Q2 2026 Earnings Call | Fri, Jul 24, 2026 · 3:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q1 2026 Earnings Call | Fri, Apr 24, 2026 · 5:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q4 2025 Earnings Call | Thu, Jan 29, 2026 · 3:30 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q3 2025 Earnings Call | Sat, Oct 25, 2025 · 5:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q2 2025 Earnings Call | Thu, Jul 24, 2025 · 4:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q4 2024 Earnings Call | Thu, Jan 30, 2025 · 3:30 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q3 2024 Earnings Call | Fri, Oct 25, 2024 · 5:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q2 2024 Earnings Call | Wed, Jul 24, 2024 · 4:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q1 2024 Earnings Call | Wed, Apr 24, 2024 · 5:00 AM ET | Replay |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 32 slides | Oct 27, 2026 |
| Q3 2026 Earnings Presentation | Earnings | 32 slides | Oct 27, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 34 slides | Jul 24, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 34 slides | Jul 24, 2026 |
| Technical Presentation (June 2026) | Technical | 45 slides | Jun 17, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 34 slides | Apr 24, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 53 slides | Jan 29, 2026 |
| Q2 2025 Earnings Presentation | Earnings | 47 slides | Jul 24, 2025 |
| souzoulabo slide | 6 slides | February 2025 | |
| FY2024 Earnings Presentation | Earnings | 56 slides | Jan 30, 2025 |
Show 50 decks
This page holds 50 of 107 decks. Open Decks
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the nine months ended September 30, 2026) | Oct 27, 2026 | Results | Tokyo Stock Exchange |
| Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS) | Oct 27, 2026 | Results | Tokyo Stock Exchange |
| F. Hoffmann-La Roche Announces Third Quarter Sales 2026 | Oct 22, 2026 | Other filings | Tokyo Stock Exchange |
| Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA | Sep 28, 2026 | Other filings | Tokyo Stock Exchange |
| CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026) | Jul 24, 2026 | Interim report | Tokyo Stock Exchange |
| F. Hoffmann-La Roche Announces Half Year Results 2026 | Jul 23, 2026 | Interim report | Tokyo Stock Exchange |
Cap table
Built by 6ix from Chugai Pharmaceutical Co., Ltd.’s releases
- Common shares
- 1,679,057,667
- Fully diluted
- 1,679,057,667
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,679,057,667 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,679,057,667 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Boris L. Zaïtra | Head of Corporate Business Development of Roche · Since at least Mar 27, 2026 |
| Hitoshi Iikura | Director, Executive Vice President · Since at least Mar 27, 2026 |
| Iwaaki Taniguchi | Director, Executive Vice President & CFO · Since at least Mar 27, 2026 |
| Masayoshi Higuchi | Audit & Supervisory Board Member (full-time) · Since at least Nov 5, 2026 |
| Osamu Okuda | Representative Director, President & CEO · Since at least Sep 9, 2026 |
| Shigehiro Yamada | Audit & Supervisory Board Member (full-time) · Since at least Nov 5, 2026 |
| Teresa A. Graham | Director · Since at least Mar 27, 2026 |
| Thomas Schinecker | Director · Since at least Mar 27, 2026 |
Log in to ask 6ix AI your own questions about Chugai Pharmaceutical Co., Ltd.